APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
NCT 03175224 Brief Summary To assess: efficacy of APL-101 as monotherapy for…
Read more arrow_forwardNCT 03175224 Brief Summary To assess: efficacy of APL-101 as monotherapy for…
Read more arrow_forwardNCT 05807035 Brief Summary Phase 1 trial to evaluate the feasibility of…
Read more arrow_forwardNCT 06219941 Brief Summary The purpose of this study is to assess…
Read more arrow_forwardNCT 06120283 Brief Summary This is a dose escalation and dose expansion…
Read more arrow_forwardNCT 05796089 Brief Summary This is a prospective, multi-centre, single arm,…
Read more arrow_forwardNCT 05523947 Brief Summary This first-in-human study will be counducted to evaluate…
Read more arrow_forwardNCT 05868174 Brief Summary This is an open label, single-arm, multicentre dose…
Read more arrow_forwardNCT 05598151 Brief Summary This is a Phase1 study to assess the…
Read more arrow_forwardNCT 06923761 Brief Summary This is a Phase I/II, open-label, first-in human…
Read more arrow_forwardNCT 05647122 Brief Summary This is a first-in-human (FIH) Phase I, multi-center,…
Read more arrow_forward